- Home
- MRVI
as 11-15-2024 4:00pm EST
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $10.33 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.39 - $11.56 | Next Earning Date: | 11-07-2024 |
| Revenue: | $276,920,000 | Revenue Growth: | -33.99% |
| Revenue Growth (this year): | -4.65% | Revenue Growth (next year): | 7.10% |
Latest Maravai LifeSciences Holdings Inc. News
MRVI Breaking Stock News: Dive into MRVI Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Wolfe Research Initiates Maravai Lifesciences at Perform
GlobeNewswire
4 days ago
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
Simply Wall St.
6 days ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
TipRanks
7 days ago
Maravai Lifesciences price target lowered to $9 from $10 at Baird
Thomson Reuters StreetEvents
8 days ago
Q3 2024 Maravai LifeSciences Holdings Inc Earnings Call
MT Newswires
8 days ago
Top Midday Decliners
MT Newswires
8 days ago
UBS Adjusts Price Target on Maravai Lifesciences to $8 From $11, Maintains Neutral Rating
MT Newswires
8 days ago
RBC Capital Adjusts Price Target on Maravai Lifesciences to $13 From $17, Maintains Outperform Rating
Compare MRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRVI Maravai LifeSciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.